OIS Index Tracks Flat US Stock Market and Healthcare Sector Performance in March

In October, we launched the OIS Index, a composite of ophthalmic growth stocks, to track the investment performance of our sector. Our goal is to highlight ophthalmology investment performance, in absolute terms and compared with broader biotech and medical device industries, as well as the stock market as a whole. The OIS Index was launched with an initial value of 1,000 on October 1; as of the market close on March 30, the OIS Index stood at 876.99.

The post-election rally, which sent US stocks steadily higher between November and February, took a pause over the past month. Between February 28 and March 30, the OIS Index gained 0.7%, tracking the flat performance of healthcare industry benchmarks and the overall US stock market. Over this period, 12 of the 32 stocks in the index increased in value, compared with about two-thirds of stocks gaining value during February.

While the OIS Index gained 0.7% over the past month, the NASDAQ Biotechnology Index (NBI) declined 1.2% and a composite of US medical device stocks gained 1.3%. The Russell 3000 Index, which represents the overall US stock market, gained 0.1%.

OIS Index – Three Month Performance

December 30, 2016 – March 30, 2017

For complete information about the OIS Index click here

Drivers of OIS Index Performance


The largest contributor to OIS Index performance in March was Omeros Corp. (+2.0% contribution to index performance, stock up 28.4%), following up a similarly strong performance in February. The stock posted a strong finish to the month on the announcement of positive Phase II clinical data in renal diseases. The second largest contributor to index performance was Glaukos Corp. (+1.3% contribution to index performance, stock up 12.7%), which reported strong quarterly results on March 1.

The largest percentage gainer in March was Imprimis Pharmaceuticals (+0.4% contribution to index performance, stock up 73%). The stock rallied following the company’s quarterly report on March 21 and announcement of a registered direct offering on March 22.

The largest negative impact on the OIS Index in March came from Spark Therapeutics (–1.5% impact on index performance, stock down 16%), and from Iridex Corp. (–0.8% impact on index performance, stock down 24%). On a percentage basis, the largest decliner in the OIS Index in March was TearLab Corp. (–0.2% impact on index performance, stock down 40%).

SHARE THIS ARTICLE WITH YOUR COLLEAGUES:

RECOMMENDED FOR YOU

AbbVie’s Big Bet to Diversify with Allergan Pays Off So Far

AbbVie’s Big Bet to Diversify with Allergan Pays Off So Far

Eyenuk’s EyeArt AI System Showing Its Value

Eyenuk’s EyeArt AI System Showing Its Value

New J&J Vision CMO Steps onto a Very Large Stage

New J&J Vision CMO Steps onto a Very Large Stage

With Fresh Funding, Eyenovia Pursues Platform for Focused Drug Delivery

With Fresh Funding, Eyenovia Pursues Platform for Focused Drug Delivery

Covid-19 Impact on Healthcare Company Valuations & Financings

Covid-19 Impact on Healthcare Company Valuations & Financings

Aldeyra Eyes Lucrative DED, Conjunctivitis Markets

Aldeyra Eyes Lucrative DED, Conjunctivitis Markets

About The Author

Michael Lachman

Michael Lachman is President of EyeQ Research, which provides market research, analytics, and strategic advisory to ophthalmic companies and investors. Previously, he was a healthcare investment research analyst with Hambrecht & Quist, ThinkEquity Partners, and SAC Capital, and worked in business development, marketing, and R&D for Johnson & Johnson and Baxter.

SUBSCRIBE TO OUR NEWSLETTER

Get The Latest News In Opthalmologic Innovation To Your Inbox.

We respect your privacy and will never send you spam.

Something went wrong. Please check your entries and try again.

SUBSCRIBE TO OIS WEEKLY

Get our monthly newsletter about the latest in opthalmologic innovation.

We respect your privacy and will never send you spam.

Something went wrong. Please check your entries and try again.

STAY CONNECTED

NEW VIDEOS

PODCASTS